JP6628416B2 - 細胞培養方法 - Google Patents
細胞培養方法 Download PDFInfo
- Publication number
- JP6628416B2 JP6628416B2 JP2016540188A JP2016540188A JP6628416B2 JP 6628416 B2 JP6628416 B2 JP 6628416B2 JP 2016540188 A JP2016540188 A JP 2016540188A JP 2016540188 A JP2016540188 A JP 2016540188A JP 6628416 B2 JP6628416 B2 JP 6628416B2
- Authority
- JP
- Japan
- Prior art keywords
- hydrogel
- cell culture
- aqueous solution
- cells
- fibrous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004113 cell culture Methods 0.000 title claims description 117
- 239000000017 hydrogel Substances 0.000 claims description 207
- 239000000463 material Substances 0.000 claims description 142
- 239000007864 aqueous solution Substances 0.000 claims description 130
- 102000034240 fibrous proteins Human genes 0.000 claims description 115
- 108091005899 fibrous proteins Proteins 0.000 claims description 115
- 102000004169 proteins and genes Human genes 0.000 claims description 71
- 108090000623 proteins and genes Proteins 0.000 claims description 71
- 235000010443 alginic acid Nutrition 0.000 claims description 48
- 229920000615 alginic acid Polymers 0.000 claims description 48
- 239000000243 solution Substances 0.000 claims description 42
- 229960001126 alginic acid Drugs 0.000 claims description 37
- 239000000783 alginic acid Substances 0.000 claims description 37
- 239000003349 gelling agent Substances 0.000 claims description 37
- 150000004781 alginic acids Chemical class 0.000 claims description 36
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 27
- 235000010413 sodium alginate Nutrition 0.000 claims description 27
- 239000000661 sodium alginate Substances 0.000 claims description 27
- 229940005550 sodium alginate Drugs 0.000 claims description 27
- 239000002243 precursor Substances 0.000 claims description 21
- 239000000872 buffer Substances 0.000 claims description 18
- 108010010803 Gelatin Proteins 0.000 claims description 17
- 239000008273 gelatin Substances 0.000 claims description 17
- 229920000159 gelatin Polymers 0.000 claims description 17
- 235000019322 gelatine Nutrition 0.000 claims description 17
- 235000011852 gelatine desserts Nutrition 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 238000012258 culturing Methods 0.000 claims description 11
- 102000016942 Elastin Human genes 0.000 claims description 9
- 108010014258 Elastin Proteins 0.000 claims description 9
- 229920002549 elastin Polymers 0.000 claims description 9
- 239000002562 thickening agent Substances 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 5
- 239000001110 calcium chloride Substances 0.000 claims description 5
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 108010067306 Fibronectins Proteins 0.000 claims description 4
- 102000016359 Fibronectins Human genes 0.000 claims description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000003431 cross linking reagent Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920000307 polymer substrate Polymers 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000001263 FEMA 3042 Substances 0.000 claims description 3
- 108010073385 Fibrin Proteins 0.000 claims description 3
- 102000009123 Fibrin Human genes 0.000 claims description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 claims description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 3
- 108010085895 Laminin Proteins 0.000 claims description 3
- 102000007547 Laminin Human genes 0.000 claims description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 3
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 3
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 3
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 3
- 108060008539 Transglutaminase Proteins 0.000 claims description 3
- 230000001464 adherent effect Effects 0.000 claims description 3
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 claims description 3
- 229910001626 barium chloride Inorganic materials 0.000 claims description 3
- 239000004703 cross-linked polyethylene Substances 0.000 claims description 3
- 229920003020 cross-linked polyethylene Polymers 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 3
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 3
- 238000010030 laminating Methods 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 229920002866 paraformaldehyde Polymers 0.000 claims description 3
- 108010004131 poly(beta-D-mannuronate) lyase Proteins 0.000 claims description 3
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 3
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 3
- 229910001631 strontium chloride Inorganic materials 0.000 claims description 3
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 claims description 3
- 229920002258 tannic acid Polymers 0.000 claims description 3
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 3
- 229940033123 tannic acid Drugs 0.000 claims description 3
- 235000015523 tannic acid Nutrition 0.000 claims description 3
- 102000003601 transglutaminase Human genes 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 140
- 210000001519 tissue Anatomy 0.000 description 50
- 238000000034 method Methods 0.000 description 31
- 238000001000 micrograph Methods 0.000 description 31
- 238000010586 diagram Methods 0.000 description 14
- 238000004132 cross linking Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 11
- 229940072056 alginate Drugs 0.000 description 11
- 238000012136 culture method Methods 0.000 description 11
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 10
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000002744 extracellular matrix Anatomy 0.000 description 9
- 230000008611 intercellular interaction Effects 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 230000001070 adhesive effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000002657 fibrous material Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- -1 polydimethylsiloxane Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000003915 cell function Effects 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001523 electrospinning Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 239000012062 aqueous buffer Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000004956 cell adhesive effect Effects 0.000 description 2
- 230000036978 cell physiology Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000000515 collagen sponge Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000001312 dry etching Methods 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 238000009751 slip forming Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001039 wet etching Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/14—Scaffolds; Matrices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F4/00—Monocomponent artificial filaments or the like of proteins; Manufacture thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Textile Engineering (AREA)
- Microbiology (AREA)
- Sustainable Development (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
- Artificial Filaments (AREA)
- Spinning Methods And Devices For Manufacturing Artificial Fibers (AREA)
- Micromachines (AREA)
Description
観察された。
Claims (19)
- アルギン酸ナトリウムおよびタンパク質が溶解された第一の水溶液を導入するための少なくとも一つの入口A1〜Am(m≧1)と、
ゲル化剤水溶液を導入するための少なくとも一つの入口G1〜Gn(n≧1)と、
入口A1〜Amおよび入口G1〜Gnにそれぞれ接続される入口流路CA1〜CAmおよびCG1〜CGnと、
入口流路CA1〜CAmおよび入口流路CG1〜CGnが同時あるいは段階的に合流する合流流路Mと、
合流流路Mの下流に存在する出口O
を有する流路構造Xに対し、
前記第一の水溶液および前記ゲル化剤水溶液をそれぞれ流路構造Xに連続的に導入し、
流路構造Xの内部において、前記第一の水溶液を連続的にゲル化してハイドロゲルを形成し、
その後、流路構造Xの外部あるいは内部において、前記ハイドロゲルに含まれる前記タンパク質を化学的に架橋し、さらに前記ハイドロゲルに含まれるアルギン酸を除去する
繊維状タンパク質材料の作製方法を用いて得られた繊維状タンパク質材料を細胞とともに細胞培養用ハイドロゲル前駆体水溶液に懸濁させ、
前記細胞培養用ハイドロゲル前駆体水溶液をゲル化させることで形成した細胞培養用ハイドロゲル内部において、前記繊維状タンパク質材料に前記細胞を付着させつつ前記細胞を培養する細胞培養方法。 - アルギン酸ナトリウムおよびタンパク質が溶解された第一の水溶液、および、アルギン酸ナトリウムが溶解された第二の水溶液を、それぞれ導入するための少なくとも二つの入口A1〜Am(m≧2)と、
ゲル化剤水溶液を導入するための少なくとも一つの入口G1〜Gn(n≧1)と、
入口A1〜Amおよび入口G1〜Gnにそれぞれ接続される入口流路CA1〜CAmおよびCG1〜CGnと、
少なくとも1つの合流点P1〜Po(o≧1)において入口流路CA1〜CAmが同時あるいは段階的に合流し、合流点P1〜Poの下流における少なくとも一つの合流点Q1〜Qp(p≧1)において入口流路CG1〜CGnが同時あるいは段階的に合流する合流流路Mと、
合流流路Mの下流に存在する出口O
を有する流路構造Xに対し、
前記第一の水溶液、前記第二の水溶液、および前記ゲル化剤水溶液をそれぞれ流路構造Xに連続的に導入し、
流路構造Xの内部において、前記第一の水溶液および前記第二の水溶液を接触させ、流路構造Xの内部において前記第一の水溶液および前記第二の水溶液を連続的にゲル化してハイドロゲルを形成し、
その後、流路構造Xの外部あるいは内部において、前記ハイドロゲルに含まれる前記タンパク質を化学的に架橋し、さらに前記ハイドロゲルに含まれるアルギン酸を除去する
繊維状タンパク質材料の作製方法を用いて得られた繊維状タンパク質材料を細胞とともに細胞培養用ハイドロゲル前駆体水溶液に懸濁させ、
前記細胞培養用ハイドロゲル前駆体水溶液をゲル化させることで形成した細胞培養用ハイドロゲル内部において、前記繊維状タンパク質材料に前記細胞を付着させつつ前記細胞を培養する細胞培養方法。 - 流路構造Xは、バッファー水溶液を導入するための少なくとも一つの入口B1〜Bq(q≧1)と、
入口B1〜Bqにそれぞれ接続し、同時あるいは段階的に合流流路Mに合流する入口流路CB1〜CBqを有しており、
入口B1〜Bqから連続的に前記バッファー水溶液を導入する
請求項1乃至2のいずれか1項に記載の細胞培養方法。 - 流路構造Xは、少なくとも部分的に、微細加工を施した平板状のポリマー基板と、平面状の他のポリマー基板を貼り合せることによって形成されている
請求項1乃至3のいずれか1項に記載の細胞培養方法。 - 流路構造Xは、その幅・深さ・直径の値のうち少なくともいずれか一つが、少なくとも部分的に300マイクロメートル以下である
請求項1乃至4のいずれか1項に記載の細胞培養方法。 - 前記第一の水溶液に含まれるアルギン酸ナトリウムの濃度は、それぞれの水溶液100mLあたり0.5g以上3g以下である
請求項1乃至5のいずれか1項に記載の細胞培養方法。 - 前記タンパク質とは、ゼラチン、コラーゲン、エラスチン、ラミニン、フィブロネクチン、の少なくともいずれかを含む
請求項1乃至6のいずれか1項に記載の細胞培養方法。 - 前記第一の水溶液に含まれる前記タンパク質の濃度は、100mLあたり0.1g以上10g以下である
請求項1乃至7のいずれか1項に記載の細胞培養方法。 - 前記ハイドロゲルは繊維状であり、また、前記ハイドロゲルの直径は少なくとも部分的に50マイクロメートル以下である
請求項1乃至8のいずれか1項に記載の細胞培養方法。 - 前記ゲル化剤水溶液および/あるいは前記バッファー水溶液は、増粘剤を含む
請求項1乃至9のいずれか1項に記載の細胞培養方法。 - 前記増粘剤とは、デキストラン、ポリエチレングリコール、メチルセルロース、ヒドロキシメチルセルロース、アルギン酸プロピレングリコール、あるいはそれらの任意の組み合わせである
請求項10に記載の細胞培養方法。 - 前記ゲル化剤水溶液は、塩化カルシウム、塩化ストロンチウム、塩化バリウム、塩化マグネシウム、塩化鉄(III)の少なくともいずれかを含む
請求項1乃至11のいずれか1項に記載の細胞培養方法。 - グルタルアルデヒド、ホルムアルデヒド、パラホルムアルデヒド、タンニン酸、ゲニピン、N−ヒドロキシコハク酸イミドを有するタンパク質架橋剤、トランスグルタミナーゼ、のうち少なくともいずれかを用いることによって前記ハイドロゲルに含まれるタンパク質を架橋する
請求項1乃至12のいずれか1項に記載の細胞培養方法。 - アルギン酸リアーゼ、クエン酸塩、エチレンジアミン四酢酸のうち少なくともいずれかを用いることによって前記ハイドロゲルに含まれるアルギン酸を除去する
請求項1乃至13のいずれか1項に記載の細胞培養方法。 - 前記細胞培養用ハイドロゲルは、
アルギン酸、架橋ポリエチレングリコール、アガロース、コラーゲン、架橋ゼラチン、フィブリン、のうち少なくともいずれか一つを主成分とした細胞培養用ハイドロゲルである
請求項1乃至14のいずれか1項に記載の細胞培養方法。 - 前記細胞培養用ハイドロゲル前駆体水溶液に懸濁させた前記繊維状タンパク質材料の体積密度は、体積割合で10%以上である
請求項1乃至15のいずれか1項に記載の細胞培養方法。 - 前記細胞培養用ハイドロゲルに包埋された細胞の濃度は、1mL当たり100万個以上である
請求項1乃至16のいずれか1項に記載の細胞培養方法。 - 細胞とは、哺乳動物由来の接着性細胞である
請求項1乃至17のいずれか1項に記載の細胞培養方法。 - 前記細胞培養用ハイドロゲルにおいて前記細胞を一定期間培養した後に、前記細胞培養用ハイドロゲルを除去し、さらに前記細胞を培養する
請求項1乃至18のいずれか1項に記載の細胞培養方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014158604 | 2014-08-04 | ||
JP2014158604 | 2014-08-04 | ||
PCT/JP2015/071799 WO2016021498A1 (ja) | 2014-08-04 | 2015-07-31 | 繊維状タンパク質材料の作製方法、および細胞培養方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2016021498A1 JPWO2016021498A1 (ja) | 2017-05-18 |
JP6628416B2 true JP6628416B2 (ja) | 2020-01-08 |
Family
ID=55263765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016540188A Active JP6628416B2 (ja) | 2014-08-04 | 2015-07-31 | 細胞培養方法 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6628416B2 (ja) |
WO (1) | WO2016021498A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11724450B2 (en) * | 2017-03-15 | 2023-08-15 | Aspect Biosystems Ltd. | Systems and methods for printing a fiber structure |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6865136B2 (ja) * | 2016-08-31 | 2021-04-28 | 花王株式会社 | ハイドロゲルファイバの製造方法 |
JP6774273B2 (ja) * | 2016-08-31 | 2020-10-21 | 花王株式会社 | ハイドロゲルファイバの製造方法 |
CN109876190A (zh) * | 2019-04-11 | 2019-06-14 | 北京大学口腔医学院 | 三维生物打印墨水的制备方法及其应用 |
WO2020262458A1 (ja) | 2019-06-28 | 2020-12-30 | 日本毛織株式会社 | 細胞シート、その製造方法及び作製キット |
WO2020262469A1 (ja) * | 2019-06-28 | 2020-12-30 | 日本毛織株式会社 | ゼラチン短繊維、その製造方法、それを含む細胞凝集体、細胞凝集体の製造方法及び作製キット |
CN114457442B (zh) * | 2022-01-19 | 2022-12-06 | 西南交通大学 | 具有集水特性的仿蛛丝中空纺锤节微纤维装置及制备方法 |
CN114480269A (zh) * | 2022-01-30 | 2022-05-13 | 上海交通大学 | 重组蛋白质水凝胶培养支架及其制备方法 |
JP7395796B1 (ja) * | 2022-06-29 | 2023-12-11 | 持田製薬株式会社 | ゲルファイバ製造装置及び製造方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8785195B2 (en) * | 2009-10-14 | 2014-07-22 | The University Of Tokyo | Covered micro gel fiber |
JP5945802B2 (ja) * | 2011-05-31 | 2016-07-05 | 国立大学法人 千葉大学 | 複合型肝細胞組織体およびその作製方法 |
-
2015
- 2015-07-31 WO PCT/JP2015/071799 patent/WO2016021498A1/ja active Application Filing
- 2015-07-31 JP JP2016540188A patent/JP6628416B2/ja active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11724450B2 (en) * | 2017-03-15 | 2023-08-15 | Aspect Biosystems Ltd. | Systems and methods for printing a fiber structure |
Also Published As
Publication number | Publication date |
---|---|
WO2016021498A1 (ja) | 2016-02-11 |
JPWO2016021498A1 (ja) | 2017-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6628416B2 (ja) | 細胞培養方法 | |
Wei et al. | Continuous fabrication and assembly of spatial cell-laden fibers for a tissue-like construct via a photolithographic-based microfluidic chip | |
Verhulsel et al. | A review of microfabrication and hydrogel engineering for micro-organs on chips | |
Onoe et al. | Cell-laden microfibers for bottom-up tissue engineering | |
Lee et al. | Application of magnetic nanoparticle for controlled tissue assembly and tissue engineering | |
Lee et al. | 3D liver models on a microplatform: well-defined culture, engineering of liver tissue and liver-on-a-chip | |
Sharifi et al. | Polycaprolactone microfibrous scaffolds to navigate neural stem cells | |
JP5945802B2 (ja) | 複合型肝細胞組織体およびその作製方法 | |
JP4950884B2 (ja) | 生体適合性荷電ポリマーにより形成されたマトリクスへの層流条件下での細胞の固定化 | |
CN201193228Y (zh) | 三维细胞培养插入件、其制造设备及成套用具 | |
JP6710000B2 (ja) | マイクロファイバ | |
Pampaloni et al. | Three-dimensional tissue models for drug discovery and toxicology | |
US20060141617A1 (en) | Multilayered microcultures | |
Maji et al. | Engineering hydrogels for the development of three-dimensional in vitro models | |
Jafari et al. | Remote control in formation of 3D multicellular assemblies using magnetic forces | |
Feng et al. | Three-dimensional printing of hydrogel scaffolds with hierarchical structure for scalable stem cell culture | |
Ewald et al. | The vascular niche in next generation microphysiological systems | |
Biju et al. | Role of three-dimensional cell culture in therapeutics and diagnostics: an updated review | |
JP6241890B2 (ja) | 血管組織およびその作製方法 | |
JP6296620B2 (ja) | 細胞評価用ハイドロゲル基材、細胞評価用ハイドロゲル基材の作製方法および細胞評価手法 | |
Song et al. | Biomaterials based on hyaluronic acid, collagen and peptides for three-dimensional cell culture and their application in stem cell differentiation | |
Mansouri et al. | Advances in removing mass transport limitations for more physiologically relevant in vitro 3D cell constructs | |
Żuchowska et al. | 3D cell models for organ-on-a-chip applications | |
Ma et al. | Microfluidics Fabrication of Soft Microtissues and Bottom‐Up Assembly | |
Guida et al. | Integrating Microstructured Electrospun Scaffolds in an Open Microfluidic System for in Vitro Studies of Human Patient-Derived Primary Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD05 | Notification of revocation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7425 Effective date: 20170913 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180627 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190603 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190711 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191126 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191202 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6628416 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |